Skip to main navigation

About
R&D
Pipeline
Investors & Media
Careers

Investors & Media

Overview
News
Events & Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
- FAQs
- Investor Contact

News

Year

October 7, 2019

NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

October 6, 2019

NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH

October 3, 2019

NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting®

August 12, 2019

NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Displaying 5 - 8 of 16

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Toolkit

© 2019 NGM Biopharmaceuticals, Inc..

All Rights Reserved.

Privacy Policy.

Top